Kite Pharma (NASDAQ:KITE) Earns Daily Media Impact Rating of 0.18

Media stories about Kite Pharma (NASDAQ:KITE) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Kite Pharma earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.931397769722 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the headlines that may have impacted Accern Sentiment’s scoring:



Several equities research analysts have recently commented on the company. Canaccord Genuity lowered Kite Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, August 29th. Wedbush raised Kite Pharma from an “underperform” rating to a “neutral” rating in a research note on Tuesday, August 29th. SunTrust Banks, Inc. lowered Kite Pharma from a “buy” rating to a “hold” rating in a research note on Monday, August 28th. BTIG Research lowered Kite Pharma from a “buy” rating to a “neutral” rating in a research note on Monday, August 28th. Finally, Guggenheim lowered Kite Pharma from a “buy” rating to a “neutral” rating and set a $128.00 target price on the stock. in a research note on Monday, August 28th. Thirteen research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $94.68.

Shares of Kite Pharma (KITE) opened at 179.79 on Friday. The firm’s market capitalization is $10.28 billion. Kite Pharma has a one year low of $39.82 and a one year high of $179.95. The company has a 50-day moving average price of $179.28 and a 200 day moving average price of $117.40.

Kite Pharma (NASDAQ:KITE) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.97) by $0.03. Kite Pharma had a negative net margin of 1,092.54% and a negative return on equity of 59.15%. The business had revenue of $10.10 million during the quarter, compared to analyst estimates of $9.59 million. During the same quarter in the previous year, the business earned ($0.91) EPS. Kite Pharma’s quarterly revenue was up 110.4% compared to the same quarter last year. Analysts expect that Kite Pharma will post ($8.24) earnings per share for the current fiscal year.

In related news, EVP Timothy L. Moore sold 12,000 shares of Kite Pharma stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $107.69, for a total value of $1,292,280.00. Following the transaction, the executive vice president now owns 61,400 shares in the company, valued at approximately $6,612,166. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Helen Susan Kim sold 26,649 shares of Kite Pharma stock in a transaction on Monday, July 31st. The stock was sold at an average price of $109.28, for a total transaction of $2,912,202.72. Following the completion of the transaction, the executive vice president now owns 28,763 shares in the company, valued at approximately $3,143,220.64. The disclosure for this sale can be found here. Insiders sold a total of 194,785 shares of company stock worth $25,776,870 in the last quarter. Insiders own 14.00% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/27/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-kite-pharma-kite-share-price.html.

About Kite Pharma

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Insider Buying and Selling by Quarter for Kite Pharma (NASDAQ:KITE)

Receive News & Ratings for Kite Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply